The Cooper Companies Announces Fourth Quarter and Full Year 2013 Results
The Cooper Companies Announces Fourth Quarter and Full Year 2013 Results
-
Fourth quarter revenue increased 4% year-over-year to
$411.9 million . Fiscal 2013 revenue increased 10% to$1,587.7 million .
-
Fourth quarter GAAP earnings per share (EPS)
$1.15 , down31 cents or 21% from last year's fourth quarter. Fiscal 2013 GAAP EPS$5.96 , up 18% from fiscal 2012.
-
Fourth quarter non-GAAP EPS
$1.48 , upone cent or 1% from last year's fourth quarter. Fiscal 2013 non-GAAP EPS$5.95 , up 15% from fiscal 2012. See "Reconciliation of Non-GAAP EPS to GAAP EPS" below.
-
Fourth quarter free cash flow
$78.3 million . Fiscal 2013 free cash flow$239.4 million .
Commenting on the results,
Fourth Quarter GAAP Operating Highlights
-
Revenue
$411.9 million , up 4% from last year's fourth quarter, 7% excluding currency.
-
Gross margin 64% compared with 64% in last year's fourth quarter. Gross margin was positively impacted by a lower royalty payment on silicone hydrogel lens sales and increased manufacturing efficiencies, offset by lower revenue due to currency, primarily the yen.
-
Operating margin 15% compared with 20% in last year's fourth quarter. The decrease was the result of
$21.1 million in costs related to the completion of the Aime divestiture. Excluding these costs, operating margin would have been 20%.
-
Depreciation
$24.1 million , up 2% from last year's fourth quarter. Amortization$7.7 million , up 5% from last year's fourth quarter.
-
Total debt increased
$101.0 million fromJuly 31, 2013 , to$344.7 million , due to the repurchase of$123.0 million or 960 thousand shares, offset by operational cash flow generation. Interest expense$1.9 million compared with$2.7 million in last year's fourth quarter.
-
Cash provided by operations
$150.3 million and capital expenditures$72.0 million resulted in free cash flow of$78.3 million .
Fourth Quarter CooperVision (CVI) GAAP Operating Highlights
-
Revenue
$327.1 million , up 3% from last year's fourth quarter, 6% in constant currency.
- Revenue by category:
Constant Currency | ||||
(In millions) | % of CVI Revenue | %chg | %chg | |
4Q13 | 4Q13 | y/y | y/y | |
Toric | $ 98.2 | 30% | 7% | 8% |
Multifocal | 31.8 | 10% | 20% | 19% |
Single-use sphere | 71.1 | 22% | -2% | 8% |
Non single-use sphere, other | 126.0 | 38% | -1% | 1% |
Total | $ 327.1 | 100% | 3% | 6% |
- Revenue by geography:
Constant Currency | ||||
(In millions) | % of CVI Revenue | %chg | %chg | |
4Q13 | 4Q13 | y/y | y/y | |
|
$ 141.7 | 43% | 2% | 2% |
EMEA | 114.3 | 35% | 12% | 8% |
|
71.1 | 22% | -7% | 11% |
Total | $ 327.1 | 100% | 3% | 6% |
- Selected revenue by material:
Constant Currency | ||||
(In millions) | % of CVI Revenue | %chg | %chg | |
4Q13 | 4Q13 | y/y | y/y | |
Silicone hydrogel | $ 146.9 | 45% | 18% | 19% |
Proclear® | $ 81.6 | 25% | 2% | 4% |
- Gross margin 64% compared with 64% in last year's fourth quarter. Gross margin was positively impacted by a lower royalty payment on silicone hydrogel lens sales and increased manufacturing efficiencies, offset by lower revenue due to currency, primarily the yen.
Fourth Quarter CooperSurgical (CSI) GAAP Operating Highlights
-
Revenue
$84.8 million , up 8% from last year's fourth quarter.
- Revenue by category:
(In millions) | % of CSI Revenue | %chg | |
4Q13 | 4Q13 | y/y | |
Office and surgical procedures | $ 55.8 | 66% | 2% |
Fertility | 29.0 | 34% | 24% |
Total | $ 84.8 | 100% | 8% |
- Gross margin 64%, compared with 64% in last year's fourth quarter.
Fiscal Year 2013 Operating Highlights
-
Revenue
$1,587.7 million , up 10% from fiscal 2012, 8% excluding currency and acquisitions.
-
CVI revenue
$1,268.3 million , up 7% from fiscal 2012, 10% in constant currency, and CSI revenue$319.4 million , up 25% from fiscal 2012, 3% excluding acquisitions.
-
Gross margin 65% compared with 64% in fiscal 2012, both GAAP and non-GAAP.
-
Operating margin 19% compared with 20% in fiscal 2012. Non-GAAP 21% from 20% in fiscal 2012.
-
Depreciation and amortization expense
$125.3 million .
-
Interest expense
$9.2 million compared with$11.8 million in fiscal 2012.
-
Cash provided by operations
$415.9 million , capital expenditures$178.1 million , insurance recovery$1.3 million and acquisition costs$0.3 million resulted in free cash flow of$239.4 million .
Other
-
As previously announced on
November 7, 2013 , Cooper completed the sale of Aime, its rigid gas permeable contact lens and solutions business inJapan , toNippon Contact Lens Inc. effectiveOctober 31 , 2013. The company recognized a fiscal 2013 charge to GAAP earnings per share of$0.26 .
2014 Guidance
The Company initiated its full year 2014 guidance. Guidance is summarized as follows:
FY14 Guidance | |
Revenues (In millions) | |
Total |
|
CVI |
|
CSI |
|
EPS | |
GAAP |
|
Non-GAAP |
|
Guidance assumes constant currency at the date of issuance.
Reconciliation of Non-GAAP EPS to GAAP EPS
To supplement our financial results presented on a GAAP basis, we use non-GAAP measures that we believe are helpful in understanding our results. The non-GAAP measures exclude the loss on divestiture of Aime, discussed above, insurance proceeds related to a business interruption claim and costs related to acquisitions. Our non-GAAP financial results and guidance are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read only in conjunction with our consolidated financial statements and guidance prepared in accordance with GAAP. Management uses supplemental non-GAAP financial measures internally to understand, manage and evaluate our business and make operating decisions. These non-GAAP measures are among the factors management uses in planning and forecasting for future periods.
In the fiscal first quarter of 2013, our non-GAAP results exclude
We also report revenue growth using the non-GAAP financial measure of constant currency revenue. Management presents and refers to constant currency information so that revenue results may be evaluated excluding the effect of foreign currency rate fluctuations. To present this information, current period revenue for entities reporting in currencies other than
Three Months Ended |
Twelve Months Ended |
|||||
2013 GAAP | Adjustments | 2013 Non-GAAP | 2013 GAAP | Adjustments | 2013 Non-GAAP | |
Operating income | $ 62,043 | $ 21,062 | $ 83,105 | $ 305,945 | $ 21,687 | $ 327,632 |
Income before income taxes | $ 61,092 | $ 21,062 | $ 82,154 | $ 312,271 | $ 7,604 | $ 319,875 |
Provision for income taxes | $ 3,779 | $ 4,699 | $ 8,478 | $ 15,365 | $ 8,221 | $ 23,586 |
Net income attributable to Cooper stockholders | $ 57,396 | $ 16,363 | $ 73,759 | $ 296,151 | $ (617) | $ 295,534 |
Diluted EPS attributable to Cooper stockholders | $ 1.15 | $ 0.33 | $ 1.48 | $ 5.96 | $ (0.01) | $ 5.95 |
Fiscal 2014 EPS Guidance | ||||||
2014 GAAP | Adjustments | 2014 Non-GAAP | ||||
Diluted EPS |
|
$ -- |
|
Conference Call and Webcast
The Company will host a conference call today at
About
Forward-Looking Statements
This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to guidance, plans, prospects, goals, strategies, future actions, events or performance and other statements which are other than statements of historical fact, including our 2013 Guidance and all statements regarding anticipated growth in our revenue, expected results of operations and integration of any acquisition are forward-looking. To identify these statements look for words like "believes," "expects," "may," "will," "should," "could," "seeks," "intends," "plans," "estimates" or "anticipates" and similar words or phrases. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties.
Among the factors that could cause our actual results and future actions to differ materially from those described in forward-looking statements are: adverse changes in the global or regional general business, political and economic conditions due to the current global economic downturn, including the impact of continuing uncertainty and instability of certain
We caution investors that forward-looking statements reflect our analysis only on their stated date. We disclaim any intent to update them except as required by law.
|
||
Consolidated Condensed Balance Sheets | ||
(In thousands) | ||
(Unaudited) | ||
|
|
|
2013 | 2012 | |
ASSETS | ||
Current assets: | ||
Cash and cash equivalents | $ 77,393 | $ 12,840 |
Trade receivables, net | 229,537 | 234,297 |
Inventories | 338,917 | 320,199 |
Deferred tax assets | 41,179 | 39,417 |
Other current assets | 60,215 | 51,107 |
Total current assets | 747,241 | 657,860 |
Property, plant and equipment, net | 739,867 | 640,255 |
Goodwill | 1,387,611 | 1,370,247 |
Other intangibles, net | 198,769 | 214,783 |
Deferred tax assets | 16,279 | 14,434 |
Other assets | 47,494 | 43,805 |
$ 3,137,261 | $ 2,941,384 | |
LIABILITIES AND STOCKHOLDERS' EQUITY | ||
Current liabilities: | ||
Short-term debt | $ 42,987 | $ 25,284 |
Other current liabilities | 278,266 | 237,268 |
Total current liabilities | 321,253 | 262,552 |
Long-term debt | 301,670 | 348,422 |
Deferred tax liabilities | 24,883 | 30,971 |
Other liabilities | 65,961 | 86,281 |
Total liabilities | 713,767 | 728,226 |
Total Cooper stockholders' equity | 2,404,535 | 2,192,751 |
Noncontrolling interests | 18,959 | 20,407 |
Stockholders' equity | 2,423,494 | 2,213,158 |
$ 3,137,261 | $ 2,941,384 | |
|
||||
Consolidated Statements of Income | ||||
(In thousands, except earnings per share amounts) | ||||
(Unaudited) | ||||
Three Months Ended | Year Ended | |||
|
|
|||
2013 | 2012 | 2013 | 2012 | |
Net sales | $ 411,852 | $ 396,301 | $ 1,587,725 | $ 1,445,136 |
Cost of sales | 147,994 | 143,537 | 560,917 | 521,126 |
Gross profit | 263,858 | 252,764 | 1,026,808 | 924,010 |
Selling, general and administrative expense | 157,247 | 152,363 | 610,735 | 564,903 |
Research and development expense | 15,819 | 14,118 | 58,827 | 51,730 |
Amortization of intangibles | 7,687 | 7,303 | 30,239 | 23,979 |
Loss on divestiture of Aime | 21,062 | -- | 21,062 | -- |
Operating income | 62,043 | 78,980 | 305,945 | 283,398 |
Interest expense | 1,900 | 2,723 | 9,168 | 11,771 |
Gain on insurance proceeds | -- | 5,000 | 14,084 | 5,000 |
Loss on extinguishment of debt | -- | -- | -- | 1,404 |
Other income, net | 949 | 1,382 | 1,410 | 229 |
Income before income taxes | 61,092 | 82,639 | 312,271 | 275,452 |
Provision for income taxes | 3,779 | 10,492 | 15,365 | 26,808 |
Net income | 57,313 | 72,147 | 296,906 | 248,644 |
Loss (income) attributable to noncontrolling interests | 83 | (227) | (755) | (305) |
Net income attributable to Cooper stockholders | $ 57,396 | $ 71,920 | $ 296,151 | $ 248,339 |
Diluted earnings per share attributable to Cooper stockholders | $ 1.15 | $ 1.46 | $ 5.96 | $ 5.05 |
Number of shares used to compute earnings per share attributable to Cooper stockholders | 49,723 | 49,386 | 49,685 | 49,152 |
Soft Contact Lens Revenue Update
Worldwide Manufacturers' Soft Contact Lens Revenue | ||||||
(U.S. dollars in millions; constant currency; unaudited) | ||||||
Calendar 3Q13 | Trailing Twelve Months 2013 | |||||
Market | CVI | Market | CVI | |||
Market | Change | Change | Market | Change | Change | |
Sales by Modality | ||||||
Single-use | $ 810 | 10% | 18% | $ 3,000 | 10% | 18% |
Other | 1,120 | 3% | 8% | 4,360 | 1% | 8% |
WW Soft Contact Lenses | $ 1,930 | 6% | 10% | $ 7,360 | 5% | 10% |
Sales by Geography | ||||||
Americas | $ 765 | 7% | 11% | $ 2,905 | 5% | 10% |
EMEA | 540 | 4% | 9% | 2,075 | 3% | 8% |
Asia Pacific | 625 | 6% | 10% | 2,380 | 5% | 14% |
WW Soft Contact Lenses | $ 1,930 | 6% | 10% | $ 7,360 | 5% | 10% |
Source: Management estimates and independent market research |
COO-E
CONTACT:Source:Kim Duncan Senior Director, Investor Relations ir@cooperco.com 925-460-3663
News Provided by Acquire Media